Previous 10 | Next 10 |
Vor Biopharma (NASDAQ:VOR): Q2 GAAP EPS of -$0.50 beats by $0.07. Cash, cash equivalents and investments were $244.6 million as of June 30, 2021. Press Release For further details see: Vor Biopharma EPS beats by $0.07
On track to report initial VOR33 clinical data in the first half of 2022 Announced collaborations with Abound Bio and Janssen to develop novel treatment systems for hematologic malignancies Initiated build-out of in-house clinical manufacturing facility ...
You can read full article here. For further details see: Wall Street Breakfast: The Week Ahead (Podcast)
Welcome to Seeking Alpha's Stocks to Watch - a preview of key events scheduled for the next week. Follow this account and turn the e-mail alert on to receive this article in your inbox every Saturday morning. A podcast of Stocks to Watch is also available on Sundays on Seeking Alpha, Apple Po...
Welcome to Seeking Alpha's Catalyst Watch - a breakdown of some of next week's actionable events that stand out. Check out Saturday morning's regular Stocks to Watch article for a full list of events planned for the week or the Seeking Alpha earnings calendar for companies due to report. Mond...
Hazal Ak/iStock via Getty Images Gelesis, makers of the weight loss pill Plenity, is going public through a reverse merger with SPAC Capstar Special Purpose Acquisition Corp. ([[CPSRU]] -0.6%). The deal is expected to give Gelesis an equity value of about $1.3B, and give the company gross pro...
CAMBRIDGE, Mass., July 08, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company), a cell therapy company pioneering engineered hematopoietic stem cell (eHSC) therapies combined with targeted therapies for the treatment of cancer, today announced the formation of a collaboratio...
Vor has a lead asset entering phase 1 clinical trials for AML that has the potential to become the standard of care for stem cell transplants. The company also has a platform and process to expand the use of their lead asset, VOR33, and design other cell therapies for beyond AML. ...
Gainers: Osmotica Pharmaceuticals (OSMT) +38%, Star Equity (STRR) +16%, Atossa Therapeutics (ATOS) +15%, Vor Biopharma (VOR) +12%, Rezolute (RZLT) +10%.Losers: Theravance Biopharma (TBPH) -8%, Corbus Pharmaceuticals (CRBP) -8%, Kaleido Bi...
CAMBRIDGE, Mass., June 17, 2021 (GLOBE NEWSWIRE) -- Vor Biopharma (Nasdaq: VOR or the Company) announced today that it will build-out an in-house clinical manufacturing facility in Cambridge, Massachusetts to support its development of potentially transformative engineered hematopoietic ste...
News, Short Squeeze, Breakout and More Instantly...
On-track for trem-cel and VCAR33 ALLO clinical updates in the second half of 2024 Trem-cel trial expanded to include patients with myelodysplastic syndromes (MDS); Mylotarg™ dosing has advanced to the third cohort CAMBRIDGE, Mass., May 09, 2024 (GLOBE NEWSWI...
CAMBRIDGE, Mass., May 02, 2024 (GLOBE NEWSWIRE) -- Vor Bio (Nasdaq: VOR), a clinical-stage cell and genome engineering company, today announced the appointment of Fouad Namouni, M.D., to its Board of Directors. Dr. Namouni currently serves as President of Research & Development at Blueprint M...
Trem-cel and VCAR33 ALLO clinical trial data expected in the second half of 2024 VCAR33 ALLO granted Fast Track and Orphan Drug Designation by U.S. Food & Drug Administration Cash runway extends into second half of 2025 CAMBRIDGE, Mass., March...